A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression
作者： M. Marttila , J. Jääskeläinen , R. Järvi , M. Romanov , E. Miettinen
DOI: 10.1016/0924-977X(95)80002-J
关键词: Anesthesia 、 Dose 、 Mirtazapine 、 Clinical trial 、 In patient 、 Depression (differential diagnoses) 、 Movement disorders 、 Doxepin 、 Psychology 、 Tolerability 、 Pharmacology (medical) 、 Biological psychiatry 、 Pharmacology 、 Neurology 、 Psychiatry and Mental health 、 Clinical neurology
摘要: Abstract One hundred and sixty-three patients with major depression were randomly assigned to treatment mirtazapine or doxepin for 6 weeks in a double-blind clinical trial. Initially, received 20 mg/day 75 mg/day, dosages then titrated up maximum of 60 300 respectively. Both drugs produced considerable improvement depressive symptoms no statistically significant differences between the two patient groups. In group only prematurely terminated study due adverse drug experiences, as compared six doxepin-treated group. Moreover, complained more frequently dry mouth movement disorders. conclusion, is an effective appears offer advantages tolerability over doxepin.
elsevier.com
sci-hub.se 参考文章(33)
Wernicke Jf, The side effect profile and safety of fluoxetine. The Journal of Clinical Psychiatry. ,vol. 46, pp. 59- 67 ,(1985)
Ward T. Smith, Edna Gilvary, Vincent Glaudin, John Panagides, Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacology Bulletin. ,vol. 26, pp. 191- 196 ,(1990)
The serotonin syndrome. American Journal of Psychiatry. ,vol. 148, pp. 705- 713 ,(1991) , 10.1176/AJP.148.6.705
David J. Kupfer, Long-term treatment of depression. The Journal of Clinical Psychiatry. ,vol. 52, pp. 28- 34 ,(1991)
CHAELES M. BEASLEY, DANIEL N. MASICA, JOHN H. HEILIGENSTEIN, DAVID E. WHEADON, ROBERT L. ZERBE, Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings Journal of Clinical Psychopharmacology. ,vol. 13, pp. 312- 320 ,(1993) , 10.1097/00004714-199310000-00003
S. A. Montgomery, J. Henry, G. McDonald, T. Dinan, M. Lader, I. Hindmarch, A. Clare, D. Nutt, Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates International Clinical Psychopharmacology. ,vol. 9, pp. 47- 53 ,(1994) , 10.1097/00004850-199400910-00008
PerttiJ. Neuvonen, Sinikka Pohjola-Sintonen, Ulrich Tacke, Erkki Vuori, Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses The Lancet. ,vol. 342, pp. 1419- 1419 ,(1993) , 10.1016/0140-6736(93)92774-N
Milana Zivkov, Geoff D. De Jongh, Org 3770 versus amitriptyline: A 6‐week randomized double‐blind multicentre trial in hospitalized depressed patients Human Psychopharmacology-clinical and Experimental. ,vol. 10, pp. 173- 180 ,(1995) , 10.1002/HUP.470100302
M. van Moffaert, J. de Wilde, A. Vereecken, M. Dierick, J. L. Evrard, J. Wilmotte, J. Mendlewicz, Mirtazapine is more effective than trazodone: A double-blind controlled study in hospitalized patients with major depression International Clinical Psychopharmacology. ,vol. 10, pp. 3- 10 ,(1995) , 10.1097/00004850-199503000-00001
S Cassidy, J Henry, Fatal toxicity of antidepressant drugs in overdose. BMJ. ,vol. 295, pp. 1021- 1024 ,(1987) , 10.1136/BMJ.295.6605.1021